Patents by Inventor Marek Zatloukal

Marek Zatloukal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8552013
    Abstract: Novel heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: October 8, 2013
    Assignee: USTAV Experimentalni Botaniky Akademie Ved Ceske Republiky
    Inventors: Igor Popa, Jan Holub, René Lenobel, Stefaan Werbrouck, Karel Dolezal, Miroslav Strnad, Marek Zatloukal, Frank J. Massino
  • Patent number: 8492391
    Abstract: The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: July 23, 2013
    Assignees: Univerzita Palackeho V Olomouci, Biopatterns, S.R.O.
    Inventors: Marek Zatloukal, Vladimir Krystof, Libor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strnad, Radek Jorda
  • Publication number: 20130040908
    Abstract: Substitution derivatives of N6-benzyladenosine-5?-monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. A Method for their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives is also disclosed.
    Type: Application
    Filed: April 28, 2011
    Publication date: February 14, 2013
    Applicants: BIOAPEX, S.R.O., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Marek Zatloukal, Karel Dolezal, Jiri Voller, Lukas Spichal, Miroslav Strnad
  • Patent number: 8222260
    Abstract: The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: July 17, 2012
    Assignees: Univerzita Palackego V Olomouci, Freie Universitat Berlin
    Inventors: Lukas Spichal, Marketa Gemrotova, Marek Zatloukal, Jitka Frebortova, Petr Galuszka, Tomas Werner, Thomas Schmulling, Karel Dolezal, Miroslav Strnad
  • Publication number: 20120070512
    Abstract: The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
    Type: Application
    Filed: June 2, 2010
    Publication date: March 22, 2012
    Inventors: Marek Zatloukal, Vladimir Krystof, Libor Havlicek, Igor Popa, Karel Dolezal, Miroslav Strnad, Radek Jorda
  • Publication number: 20120071433
    Abstract: The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.
    Type: Application
    Filed: May 12, 2010
    Publication date: March 22, 2012
    Inventors: Lucie Szucova, Viadimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Lukas Spichal
  • Patent number: 8119614
    Abstract: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound and use of these derivatives for preparation of pharmaceutical compositions, in biotechnological processes, in cosmetics and in agriculture.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: February 21, 2012
    Assignee: Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky
    Inventors: Karel Dolezal, Igor Popa, Marek Zatloukal, René Lenobel, Dana Hradecká, Borivoj Vojtesek, Stjepan Uldrijan, Petr Mlejnek, Stefaan Werbrouck, Miroslav Strnad
  • Publication number: 20110287111
    Abstract: The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.
    Type: Application
    Filed: January 22, 2010
    Publication date: November 24, 2011
    Inventors: Libor Havlicek, Vladimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Borivoj Vojtesek
  • Publication number: 20110230503
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are provided. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 22, 2011
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Publication number: 20110224238
    Abstract: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 15, 2011
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Ludek Frolich, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Patent number: 7960397
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts of the following general formula are provided wherein R6 and R9 are as defined in the specification. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for application to mammalian cells, and especially human skin cells, in order to improve the cosmetic appearance of the mammalian cells, especially human skin.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: June 14, 2011
    Assignee: Institute of Experimental Botany, Academy of Sciences of the Czech Republic
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Publication number: 20100234401
    Abstract: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.
    Type: Application
    Filed: May 24, 2010
    Publication date: September 16, 2010
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Ludek Frohlich, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Publication number: 20100190806
    Abstract: The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.
    Type: Application
    Filed: July 2, 2008
    Publication date: July 29, 2010
    Inventors: Lukas Spichal, Marketa Gemrotova, Marek Zatloukal, Jitka Frebortova, Petr Galuszka, Tomas Werner, Thomas Schmulling, Karel Dolezal, Miroslav Strnad
  • Publication number: 20090170879
    Abstract: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are provided. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting from or associated with inflammation, and the like.
    Type: Application
    Filed: December 28, 2007
    Publication date: July 2, 2009
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Jiri Voller, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Publication number: 20080014227
    Abstract: Novel heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 17, 2008
    Inventors: Igor Popa, Jan Holub, Rene Lenobel, Stefaan Werbrouck, Karel Dolezal, Miroslav Strnad, Marek Zatloukal, Frank Massino
  • Publication number: 20080009508
    Abstract: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 10, 2008
    Inventors: Lucie Szucova, Marek Zatloukal, Lukas Spichal, Ludek Frohlich, Karel Dolezal, Miroslav Strnad, Frank J. Massino
  • Patent number: 7279482
    Abstract: Heterocyclic derivatives based on N6-substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6?-X, X is —NH—, and R6? is substituted phenyl or substituted benzyl. The derivatives possess anticancer, mitotic, imunosuppressive and antisenescent properties for plant, animal and human cells, and methods of their preparation are disclosed. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: October 9, 2007
    Assignee: Ústav experimentálni botaniky Akademie ved Ceské republiky
    Inventors: Karel Dolezal, Igor Popa, Jan Holub, René Lenobel, Stefaan Werbrouck, Miroslav Strnad, Marek Zatloukal
  • Publication number: 20060166925
    Abstract: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound and use of these derivatives for preparation of pharmaceutical compositions, in biotechnological processes, in cosmetics and in agriculture.
    Type: Application
    Filed: December 29, 2003
    Publication date: July 27, 2006
    Inventors: Karel Dolezal, Igor Popa, Marek Zatloukal, Rene Lenobel, Dana Hradecka, Borivoj Vojtesek, Stjepan Uldrijan, Petr Mlejnek, Stefaan Werbrouck, Miroslav Strnad
  • Publication number: 20050043328
    Abstract: New heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, imunosuppressive and antisenescent propoerties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
    Type: Application
    Filed: August 1, 2002
    Publication date: February 24, 2005
    Inventors: Karel Dolezal, Igor Popa, Jan Holub, Rene Lenobel, Stefaan Werbrouck, Miroslav Strnad, Marek Zatloukal